BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34786182)

  • 1. Anaplastic lymphoma kinase rearrangement prevalence in patients with advanced non-small cell lung cancer in the United States: retrospective real world data.
    Allen TC; Xiao Y; Yang B; Croix D; Abraham A; Redpath S; Engstrom-Melynk J; Shah R; Madala J; Bernicker EH
    Oncotarget; 2021 Nov; 12(23):2308-2315. PubMed ID: 34786182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to National Comprehensive Cancer Network ALK Testing Guidelines for Patients with Advanced Non-Small Cell Lung Cancer in U.S. Community Medical Centers.
    Bernicker EH; Xiao Y; Abraham A; Yang B; Croix DA; Redpath S; Engstrom-Melnyk J; Shah R; Madala J; Allen TC
    Oncologist; 2021 Jun; 26(6):e1050-e1057. PubMed ID: 33823082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world anaplastic lymphoma kinase (ALK) rearrangement testing patterns, treatment sequences, and survival of ALK inhibitor-treated patients.
    Davies J; Martinec M; Coudert M; Delmar P; Crane G
    Curr Med Res Opin; 2019 Mar; 35(3):535-542. PubMed ID: 30296185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Data on the Prevalence of Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer in the Middle East and North Africa.
    Jazieh AR; Gaafar R; Errihani H; Jaafar H; Al Dayel F; Bahnassy AA; El Kadi H; Abdallah MM; Zaatari G
    JCO Glob Oncol; 2021 Sep; 7():1556-1563. PubMed ID: 34788123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study.
    Liang H; Song X; Zhang Y; Zhang S; Li F; Fang J; Li J; Liang L; Nie L; Ma K; Zhang L; Wang X; Xu J; Wei Y; Wang J; Song Q; Tian G; Mu Y; Gu Y; Yang L; Sun P; Zhong W; Zhao J; Xu Y; Chen M; Wang M
    Thorac Cancer; 2019 Jul; 10(7):1521-1532. PubMed ID: 31144459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer.
    Guérin A; Sasane M; Zhang J; Macalalad AR; Galebach P; Jarvis J; Kageleiry A; Culver K; Wu EQ; Wakelee H
    Cancer Epidemiol; 2015 Jun; 39(3):307-12. PubMed ID: 25914136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic characteristics and therapeutic responses of Chinese patients with non-small cell lung cancer who harbor an anaplastic lymphoma kinase rearrangement.
    Fu S; Wang HY; Wang F; Huang MY; Deng L; Zhang X; Ye ZL; Shao JY
    Chin J Cancer; 2015 Aug; 34(9):404-12. PubMed ID: 26253541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for anaplastic lymphoma kinase (ALK) gene rearrangements in non-small-cell lung cancer in New Zealand.
    McKeage MJ; Tin Tin S; Khwaounjoo P; Sheath K; Dixon-McIver A; Ng D; Sullivan R; Cameron L; Shepherd P; Laking GR; Kingston N; Strauss M; Lewis C; Elwood M; Love DR
    Intern Med J; 2020 Jun; 50(6):716-725. PubMed ID: 31318119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaplastic lymphoma kinase rearrangements in patients with non-small cell lung cancer in Jordan.
    Maraqa B; Al-Ashhab M; Sughayer MA
    J Int Med Res; 2022 Jun; 50(6):3000605221104181. PubMed ID: 35689392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage.
    Kim TJ; Park CK; Yeo CD; Park K; Rhee CK; Kim J; Kim SJ; Lee SH; Lee KY; Yoon HK
    J Surg Oncol; 2014 Sep; 110(3):245-51. PubMed ID: 24888607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of anaplastic lymphoma kinase rearrangements in Moroccan patients with non small cell lung cancer: a multi-institutional national retrospective study.
    El Yacoubi H; Sow ML; Kettani F; Gamra L; Mestari A; Jabri L; Elghissassi I; Errihani H
    BMC Cancer; 2020 May; 20(1):479. PubMed ID: 32460789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma.
    Sun JM; Lira M; Pandya K; Choi YL; Ahn JS; Mao M; Han J; Park K; Ahn MJ; Kim J
    Lung Cancer; 2014 Feb; 83(2):259-64. PubMed ID: 24300132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review.
    Zhang B; Zhang Y; Xu J; Zhang X; Chu T; Wang S; Qian J; Qiao R; Lu J; Zhang L; Han B
    Target Oncol; 2018 Oct; 13(5):631-639. PubMed ID: 30218431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of EGFR and ALK mutation frequency and treatment results in advanced non-small cell lung cancer.
    Komurcuoglu B; Karakurt G; Kaya OO; Diniz G; Kırbıyık O; Evkan A; Yalnız E
    J Cancer Res Ther; 2023 Apr; 19(Supplement):S183-S190. PubMed ID: 37147996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological and computed tomography features of patients with early-stage non-small-cell lung cancer harboring ALK rearrangement.
    Hou X; Chen H; Liu Y; Gong S; Zhudai M; Shen L
    Cancer Imaging; 2023 Feb; 23(1):20. PubMed ID: 36823653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis.
    Fan L; Feng Y; Wan H; Shi G; Niu W
    PLoS One; 2014; 9(6):e100866. PubMed ID: 24959902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
    Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
    BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world ALK Testing Trends in Patients With Advanced Non-Small-Cell Lung Cancer in the United States.
    Lin HM; Wu Y; Yin Y; Niu H; Curran EA; Lovly CM; Humphries MJ
    Clin Lung Cancer; 2023 Jan; 24(1):e39-e49. PubMed ID: 36376172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan.
    Isobe H; Mori K; Minato K; Katsura H; Taniguchi K; Arunachalam A; Kothari S; Cao X; Kato T
    Lung Cancer (Auckl); 2017; 8():191-206. PubMed ID: 29123433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.